Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 20;9:8863. doi: 10.1038/s41598-019-45345-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Voriconazole plasma concentration in carriers or non-carriers of the rs12248560 variant. (A) Dose-corrected voriconazole plasma concentrations of the 33 patients are shown. The carriers had a mean of 0.034 µg/mL/mg/kg/day and showed significantly lower concentrations than non-carriers (p = 0,011), whose mean was 0.046 µg/mL/mg/kg/day. The mean and the standard deviation for each genotype are plotted. (B) First trough plasma concentrations of voriconazole, without dose correction, reached by the patients studied (p = 0.054). Almost all the concentrations belonging to the carriers of the rs12248560 variant were sub-therapeutic (median 0.37 µg/mL), whereas for the non-carriers the concentrations were spread out (median 1.12 µg/ml). The medians and interquartile ranges are plotted and the therapeutic range (between 1 and 6 µg/mL) is highlighted. (C) First dose-corrected voriconazole concentration of the 33 patients is shown. The median for each genotype were 0.10 and 0.029 µg/mL/mg/kg/day for non-carriers and carriers of the rs12248560 variant, respectively (p = 0.059).